PA
FULC icon

Profund Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Profund Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Buy
+15,501
New +$144K ﹤0.01% 1063
2024
Q4 		– Sell
-34,846
Closed -$124K – 1146
2024
Q3 		$124K Buy
34,846
+23,925
+219% +$177K ﹤0.01% 1095
2024
Q2 		$67.7K Buy
+10,921
New +$82.7K ﹤0.01% 1062

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Profund Advisors's FULC Position: Q1 2026 in Review

Profund Advisors opened a new position in Fulcrum Therapeutics (FULC) in Q1 2026: 15,501 shares worth $119K. The stake represents ﹤0.01% of the portfolio and ranks #1063 among its holdings. This is a return to the name: Profund Advisors previously reported a position in FULC as recently as Q3 2024.

Profund Advisors first reported a position in FULC in Q2 2024 and has held it in 3 quarters since. The position peaked at $124K in Q3 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Profund Advisors held 15,501 shares of Fulcrum Therapeutics worth $119K as of Q1 2026.
  • Fulcrum Therapeutics was a new Profund Advisors position in Q1 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of Profund Advisors's portfolio in Q1 2026, its #1063 holding.
  • Profund Advisors first reported a position in Fulcrum Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Profund Advisors's Fulcrum Therapeutics position peaked at $124K in Q3 2024.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.